Treatment Trial Evaluating Long Acting Insulin in Type 1 Diabetes
Patients with type 1 diabetes trained in multiple daily insulin injection were treated with
two diffferent kinds of long acting insulin preparations. The two insulin preparations were
glargine and ultralente insulin. Patients were randomized to receive one of the two insulin
preparations for the first 4 months followed by the second preparation for a further four
months. Short acting insulin used was the same during both periods. We found that glargine
insulin was better than ultralente insulin in our study.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.